Acute,Leukemia, Lymphoid Clinical Trial
Official title:
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
| Verified date | August 2022 |
| Source | Institute of Hematology & Blood Diseases Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
In this single-center, open-label, no control,prospective clinical trial, a total of 30 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients will be enrolled. Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT) or autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy. The purpose of current study is to determine the clinical efficacy and tolerability of combination therapy of Dasatinib with multi-agent chemotherapy in newly-diagnosed Ph+ ALL.
| Status | Completed |
| Enrollment | 30 |
| Est. completion date | December 31, 2021 |
| Est. primary completion date | December 31, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 55 Years |
| Eligibility | Inclusion Criteria: 1. Patients aged 18 to 60 years with De novo Philadelphia chromosome positive (Philadelphia chromosome positive or BCR/ABL transcript positive) acute lymphoblastic leukemia. 2. Eastern Cooperative Oncology Group (ECOG) Performance status 2. 3. Adequate end organ function as defined by: Total bilirubin = 1.5 x upper limit of normal(ULN); serum glutamic-oxaloacetic transaminase(SGOT) and serum glutamic pyruvic transaminase(SGPT) = 2.5 x ULN; Creatinine = 1.5 x ULN; Serum amylase and lipase = 1.5 x ULN; Alkaline phosphatase = 2.5 x ULN unless considered tumor related; Patients must have adequate cardiac function (ejection fraction = 45 % on Multiple Gated Acquisition (MUGA) scan). 4. Patients must have the following laboratory values (= lower limit of normal (LLN) or corrected to within normal limits with supplements prior to the first dose of study medication.): Potassium = LLN; Magnesium = LLN; Phosphorus = LLN 5. Patients should sign informed consent form. Exclusion Criteria: 1. Impaired cardiac function: Long QT syndrome or a known family history of long QT syndrome; clinically significant resting brachycardia (<50 beats per minute); ejection fraction < 45 % on MUGA scan. QTc interval > 450 msec on baseline ECG (using the QTcF formula). If QTcF interval>450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc. Myocardial infarction within 12 months prior to starting study; other clinically significant heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias). Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. 2. Other concurrent severe and/or uncontrolled medical conditions: Patients with another primary malignant disease, except those that do not currently require treatment; acute or chronic liver, pancreatic or severe renal disease; another severe and/or life-threatening medical disease. 3. Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) male or female of childbearing potential unwilling to use contraceptive precautions throughout the trial (post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential). 4. Who is known human deficiency virus (HIV) positive. 5. Use of any other investigational agent in the last 30 days. |
| Country | Name | City | State |
|---|---|---|---|
| China | Institute of Hematology & Blood Diseases Hospital | Tianjin | Tianjin |
| Lead Sponsor | Collaborator |
|---|---|
| Institute of Hematology & Blood Diseases Hospital |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall survival (OS) | From date of diagnosis until the date of death from any cause, assessed up to 60 months. | ||
| Secondary | Disease-free survival (DFS) | From the date of complete remission(CR) until the date of documented relapse,assessed up to 60 months. | ||
| Secondary | The complete remission (CR) rate | Participants will be followed for the duration of the treatment, an expected average of 6 months. | ||
| Secondary | The molecular CR rate | Participants will be followed for the duration of the treatment, an expected average of 24 months. | ||
| Secondary | The plasma level of dasatinib in the regimen | Up to 3 months. | ||
| Secondary | The Cerebrospinal fluid level of dasatinib in the regimen | Up to 6 months. | ||
| Secondary | Number of adverse event of combined treatment | Participants will be followed for the duration of the treatment, an expected average of 24 months. | ||
| Secondary | Grade of adverse event of combined treatment | Participants will be followed for the duration of the treatment, an expected average of 24 months. |